What Is Cytosorbents Corporation (CTSO) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Cytosorbents Corporation's intrinsic value is estimated at $0.54, presenting a divided outlook at the current price of $0.39. With an average implied return of +40.0% across a split 6–4 (bull–bear) consensus, the model spread of +404.0% underscores analytical uncertainty. Notably, EPV sees the most upside at +312.8% (fair value: $1.61), while Bayesian DCF is the most conservative at -91.2% ($0.03). The spread between these extremes — +404.0% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About CTSO?
11 of 13 models are currently active for CTSO. Of these, 7 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates CTSO's intrinsic value at $0.03, implying -91.2% downside from the current price. See which stocks rank higher →
How Does CTSO Rank in Surgical & Medical Instruments & Apparatus?
Among 109 Surgical & Medical Instruments & Apparatus stocks, CTSO ranks #69 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.
See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →
Cytosorbents Corporation operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is CTSO a Value Trap?
CirclFi's Value Trap algorithm assigns CTSO a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Cytosorbents Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Cytosorbents Corporation is rated at 5.9/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +404.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CTSO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CTSO's 11 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad